Caregivers' perspectives on lecanemab use for Alzheimer's disease: A national survey in China.

Caregivers' decisions significantly influence Alzheimer's disease progression, yet research on the benefits of disease-modifying therapy (DMT) from their perspective is limited. This cross-sectional survey included 345 informal caregivers of lecanemab-treated patients. We collected online questionnaires from 37 tertiary hospitals across 31 provinces/autonomous regions/municipalities in China (2024/06/24 ∼ 2024/12/24). Approximately 94.5% of the caregivers opined that the burden of care did not intensify (including remaining constant or being alleviated) subsequent to the administration of lecanemab, among which 25.8% of the caregivers stated that the burden of care was mitigated. Those caregivers with a higher annual family income (≥¥400,000, p < 0.01) and filial caregivers exhibited greater confidence in the therapeutic efficacy of lecanemab. Most caregivers hold a positive attitude toward lecanemab, particularly filial caregivers. The application of lecanemab may alleviate the care burden on caregivers. We conducted the first China national survey on Alzheimer's disease (AD) caregiver decision-making and lecanemab experience, collecting 345 questionnaires. The majority of caregivers in China hold a favorable attitude toward lecanemab. Higher education, younger age, and filial relationships are associated with reduced caregiver burden. Higher income is linked to increased caregiver confidence and better lecanemab adherence. There is a low adoption rate of blood-based AD biomarkers in caregiver decisions.